This CME/CE program will provide clinicians with an update on treatment strategies for basal insulins to manage time-in-range and glucose variability to improve outcomes in patients with diabetes. The expert faculty will review the importance of the role of the diabetes care and education specialist to minimize glucose variability in patients on longer-acting insulins. Next, a clinical review of newer longer-acting insulins in patients with diabetes will be analyzed. Following, strategies to optimize treatment plans and how to educate the person with diabetes will be discussed. Upon completion of this activity, learners will be better equipped to treat and manage their patients with diabetes.
General practitioners, diabetes educators, nurses, pharmacists, and others interested in the management of patients with diabetes
I. A Closer Look into the Importance of the Role of the Diabetes Care and Education Specialist to Minimize Glucose Variability in Patients on Longer-acting Insulins
II. Clinical Review of Newer Longer-acting Insulins in Patients with Diabetes
III. Strategies to Optimize Treatment Plans and Educate the Person with Diabetes
- Recognize the importance of improving patients’ glucose to time-in-range, minimizing glucose variability, and incorporating continuous glucose monitoring in patients with diabetes
- Distinguish between insulins and incorporate them into practice in patients with diabetes
- Tailor treatment plans with the interprofessional team and the activated patient with diabetes
Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP
Endocrine Clinical Pharmacy Specialist
CGM and Remote Monitoring Program Coordinator
Co-Director Center of Excellence for Endocrine Disorders in Pregnancy
Cleveland Clinic Endocrinology & Metabolism Institute
Susan Weiner, MS, RDN, CDCES, FADCES
Diabetes in Real Life Columnist, Endocrine Today
Certified Diabetes Care & Education Specialist
Owner and Clinical Director, Susan Weiner Nutrition, PLLC
Disclosures of Relevant Financial Relationships
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships relating to the topics of this educational activity. Any relevant financial relationships are mitigated via a content review by planning committee members and faculty with no relevant financial relationships.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
|Faculty||Relationship Identified With:|
|Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP||Consultant/Advisor: CeQur; Insulet Corporation; Lilly; Medtronic; Sanofi US
Speaker’s Bureau: Abbott; Dexcom, Inc.; Novo Nordisk
|Katelyn O’Brien, PharmD, BCPS, CDCES, BC-ADM||Nothing to disclose|
|Susan Weiner, MS, RDN, CDCES, FADCES||Nothing to disclose|
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Chelsey Benedek and Nicole McMenamin hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council forPharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit TM.
AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour (Provider #P0491).
AcademicCME designates this continuing education activity for 1.0 CPE Contact Hour (0.10 CEUs) of continuing pharmacy education credit (UAN JA4008190-0000-22-010-H04-P).
Clinicians should only claim credit commensurate with the extent of their participation.
This activity has been supported by independent educational grant Sanofi US.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Sanofi US do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 50% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].